India, June 9 -- Artificial intelligence (AI) is no longer a future possibility for the life sciences industry, it is rapidly becoming a foundational capability. From accelerating drug discovery and optimizing clinical trials to strengthening quality management and regulatory compliance, AI is poised to transform every stage of the pharmaceutical value chain.

Despite the various opportunities offered by AI, a less-discussed factor is emerging as the true differentiator between AI leaders and laggards - policy clarity. Today, the biggest challenge AI adoption in life sciences in facing is not technological readiness. It is the absence of clear frameworks that enable organizations to innovate confidently while remaining compliant, ethical,...